About
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Investors
Contact Us
Science
Overview
Mechanisms of Action
Publications and Presentations
Pipeline
Overview
AO-176 Solid Tumors
AO-176 Hematologic Malignancies
Expanded Access Policy
News
Overview
Press Releases
Events
Careers
Overview
Opportunities
Arch Benefits
Reach us at
info@archoncology.com
press releases
August 2, 2021
Arch Oncology Strengthens Medical and Clinical Leadership Teams with Key Appointments
April 27, 2021
Arch Oncology Secures $105 Million Series C Financing
April 10, 2021
Arch Oncology Presents New Preclinical T-ALL Data on Highly-differentiated Anti-CD47 Antibody AO-176 at AACR 2021
April 7, 2021
Arch Oncology Appoints Laurence Blumberg, M.D. President and CEO
March 10, 2021
Arch Oncology Announces Two New Preclinical Data Presentations on Highly Differentiated Anti-CD47 Antibody AO-176 at AACR 2021
February 16, 2021
Arch Oncology to Participate in Upcoming Conferences
February 9, 2021
Arch Oncology to Collaborate with Merck on Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Select Solid Tumors
January 6, 2021
Arch Oncology to Present at 39th Annual J.P. Morgan Healthcare Conference
December 7, 2020
Arch Oncology Announces First Patient Dosed in Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Multiple Myeloma
December 6, 2020
Arch Oncology Presents New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at ASH 2020
November 16, 2020
Arch Oncology Appoints Ronald Krasnow, Esq. as Chief Operating Officer
November 9, 2020
Arch Oncology to Present New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at SITC 2020
October 26, 2020
Arch Oncology to Present at Upcoming Conferences
October 5, 2020
Arch Oncology Advances Anti-CD47 Antibody AO-176 into Chemotherapy Combination Phase 1/2 Trial in Solid Tumors
June 22, 2020
Arch Oncology Announces Formation of Scientific Advisory Board
April 21, 2020
Arch Oncology Appoints Biotechnology Industry Veteran Julie Hambleton, M.D. to Board of Directors
August 12, 2019
Arch Oncology Appoints Drew Dennison to Board of Directors
May 22, 2019
Arch Oncology Appoints Kirk Christoffersen as Chief Business Officer
March 29, 2019
Arch Oncology to Present Preclinical Data on Highly-differentiated Anti-CD47 Antibody AO-176 at the AACR Annual Meeting 2019
March 25, 2019
Arch Oncology Raises $50 Million Series B Financing
February 6, 2019
Arch Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of AO-176, an Anti-CD47 Antibody with a Best-in-class Profile
